Mink Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Mink Therapeutics To Provide Corporate Update And Third Quarter 2024 Financial Report
Brief: Mink Therapeutics Files For Shelf Of Up To 4.6 Mln Shares By Selling Stockholder
Mink Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Mink Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Mink Therapeutics Regains Compliance With Nasdaq Capital Market Requirement
Mink Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: MiNK Therapeutics Announces $5.8 Mln Private Placement and Appointment of Board Observer
Mink Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Mink Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Mink Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: MiNK Announces Preclinical Data Showcasing Activity Of MiNK-215 Against Colorectal Cancer Liver Metastases
Brief: Garo Armen Reports 9.68% Stake In Mink Therapeutics Inc As Of January 16 - SEC Filing
Health Rounds: New weight-loss drug lowers blood pressure
Brief: Mink Therapeutics' Agent-797 Shows Promising Results In The Treatment Of Severe Acute Respiratory Distress
Brief: Immunoscape And Mink Therapeutics Collaborate To Accelerate Novel Tcr Identification And Therapeutic Development
Brief: Mink Therapeutics - Ended Q3 With Cash Balance Of $6.4 Million
Mink Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Mink Therapeutics Inc reports results for the quarter ended in June - Earnings Summary